The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 12, 2002, Pages 1684-1688

  Langerød, Anita ^a   Bukholm, Ida R K ^a,c   Bregård, André ^a   Lønning, Per Eystein ^b   Andersen, Tone Ikdal ^a,d   Rognum, Torleiv O ^a   Meling, Gunn Iren ^a   Lothe, Ragnhild A ^a   Børresen Dale, Anne Lise ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE;

ALLELE; ARTICLE; BREAST CANCER; COLORECTAL CARCINOMA; DNA SEQUENCE; GENE; GENE MUTATION; GENE TP53; GENETIC POLYMORPHISM; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; MUTATION RATE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0036911840     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Hainaut, P., and Hollstein, M. p53 and human cancer: The first ten thousand mutations. Adv. Cancer Res., 77: 81-137, 2000.
2. Själander, A., Birgander, R., Hallmans, G., Cajander, S., Lenner, P., Athlin, L., Beckman, G., and Beckman, L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis (Lond.), 17: 1313-1316, 1996.
3. Weston, A., and Godbold, J. H. Polymorphisms of H-ras-I and p53 in breast cancer and lung cancer: A meta-analysis. Environ. Health Perspect., 105 (Suppl. 4): 919-926, 1997.
4. Papadakis, E. N., Dokianakis, D. N., and Spandidos, D. A. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol. Cell. Biol. Res. Commun., 3: 389-392, 2000.
5. Själander, A., Birgander, R., Athlin, L., Stenling, R., Rutegard, J., Beckman, L., and Beckman, G. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis (Lond.), 16: 1461-1464, 1995.
6. Murata, M., Tagawa, M., Kimura, M., Kimura, H., Watanabe, S., and Saisho, H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis (Lond.), 17: 261-264, 1996.
7. Sayhan, N., Yazici, H., Budak, M., Bitisik, O., and Dalay, N. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res. Commun. Mol. Pathol. Pharmacol., 109: 25-34, 2001.
8. Thomas, M., Kalita, A., Labrecque, S., Pim, D., Banks, L., and Matlashewski, G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol., 19: 1092-1100, 1999.
9. Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., James, N., McGregor, J. M., Harwood, C. A., Yulug, I. G., Vousden, K. H., Allday, M. J., Gusterson, B., Ikawa, S., Hinds, P. W., Crook, T., and Kaelin, W. G. J. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet., 25: 47-54, 2000.
10. Tada, M., Furuuchi, K., Kaneda, M., Matsumoto, J., Takahashi, M., Hirai, A., Mitsumoto, Y., Iggo, R. D., and Moriuchi, T. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis (Lond.), 22: 515-517, 2001.
11. Andersen, T. I., Holm, R., Nesland, J. M., Heimdal, K. R., Ottestad, L., and Børresen, A. L. Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer, 68: 540-548, 1993.
12. Bukholm, I. K., Nesland, J. M., Karesen, R., Jacobsen, U., and Børresen, A. L. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J. Pathol., 181: 140-145, 1997.
13. Geisler, S., Lønning, P. E., Aas, T., Johnsen, H., Fluge, O., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., and Børresen, A. L. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res., 61: 2505-2512, 2001.
14. Borresen-Dale, A. L., Lothe, R. A., Meling, G. I., Hainaut, P., Rognum, T. O., and Skovlund, E. TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival. Clin. Cancer Res., 4: 203-210, 1998.
15. Ara, S., Lee, P. S., Hansen, M. F., and Saya, H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res., 18: 4961, 1990.
16. Børresen-Dale, A. L., Hovig, E., and Smith-Sørensen, B. Detection of mutations by denaturing gradient gel electrophoresis. Current Protocols in Human Genetics, pp. 7.5.1-7.5.13, 1998.
17. Børresen-Dale, A. L., Lystad, S., and Langerød, A. Temporal temperature gradient gel electrophoresis on the DCode system. Bio. Rad. Bull., 2133: 12-13, 1997.
18. Campomenosi, P., Monti, P., Aprile, A., Abbondandolo, A., Frebourg, T., Gold, B., Crook, T., Inga, A., Resnick, M. A., Iggo, R., and Fronza, G. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene, 20: 3573-3579, 2001.
19. Di Como, C. J., Gaiddon, C., and Prives, C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol., 19: 1438-1449, 1999.